The value of ultrasound (US) in the diagnosis of prostate cancer has dramatically increased in the past decade. This is mainly related to the increasing incidence of prostate cancer, the most common cancer in men and one of the most important causes of death from cancer in men. The value of conventional gray-scale US for prostate cancer detection has been extensively investigated, and has shown a low sensitivity and specificity. Therefore conventional gray-scale US is mainly used by urologists for guiding systematic prostate biopsies. With the development of new US techniques, such as color and power Doppler US, and the introduction of US contrast agents, the role of US for prostate cancer detection has dramatically changed. Advances in US techniques were introduced to further increase the value of US contrast agents. Although most of these developments in US techniques, which use the interaction of the contrast agent with the transmitted US waves, are very sensitive for the detection of microbubbles, they are mostly unexplored, in particular for prostate applications. Early reports of contrast-enhanced US investigations of blood flow of the prostate have shown that contrast-enhanced US adds important information to the conventional gray-scale US technique. Furthermore, elastography or `strain imaging' seems to have great potential in prostate cancer detection. Since these new advances in US are very sophisticated and need a long learning curve, radiologists, who are overall better trained with these new US techniques, will play a more important role in prostate cancer diagnosis. Current trends show that these new US techniques may allow for targeted biopsies and therefore replace the current `gold standard' for prostate cancer detection---the systematic biopsy. Consequently the use of these new US techniques for the detection and clinical staging of prostate cancer is promising. However, future clinical trials will be needed to determine if the promise of these new US advances of the prostate evolves into clinical application.

Author

Ferdinand Frauscher, Johann Gradl and Leo Pallwein

Contact Details

Corresponding address:
Ferdinand Frauscher, MD,
Department of Radiology II,
Medical University Innsbruck,
Anichstrasse 35, 6020 Innsbruck,
Austria

Reference

ICIS Cancer Imaging Volume 5 Special Issue A
DOI: 10.1102/1470-7330.2005.0041

Date Posted

24 November 2005

Print PDF

Size

238.35 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	3 seconds
64 Kb/s (ISDN):	29 seconds
33.3 Kb/s (Typical Modem):	57 seconds

Screen PDF

Size

369.39 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	5 seconds
64 Kb/s (ISDN):	46 seconds
33.3 Kb/s (Typical Modem):	1 minute 28 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.